

Stergios A. Polyzos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2027554/publications.pdf>

Version: 2024-02-01

422
papers

13,036
citations

26567

56
h-index

39575

94
g-index

427
all docs

427
docs citations

427
times ranked

13933
citing authors

#	ARTICLE	IF	CITATIONS
1	Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 82-97.	1.5	679
2	Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 313-326.	1.5	272
3	Nonalcoholic Fatty Liver Disease: The Pathogenetic Roles of Insulin Resistance and Adipocytokines. <i>Current Molecular Medicine</i> , 2009, 9, 299-314.	0.6	270
4	Clinical Features of 24 Patients With Rebound-associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1291-1296.	3.1	270
5	Adipokines in nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1062-1079.	1.5	250
6	The role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 365-383.	2.2	220
7	Leptin's Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals. <i>Endocrine Reviews</i> , 2013, 34, 377-412.	8.9	212
8	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. <i>Metabolism: Clinical and Experimental</i> , 2017, 71, 17-32.	1.5	208
9	Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. <i>Diabetologia</i> , 2016, 59, 30-43.	2.9	186
10	Pharmacotherapy of obesity: Available medications and drugs under investigation. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 170-192.	1.5	184
11	Irisin in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 207-217.	1.5	179
12	Leptin at the Intersection of Neuroendocrinology and Metabolism: Current Evidence and Therapeutic Perspectives. <i>Cell Metabolism</i> , 2013, 18, 29-42.	7.2	178
13	Irisin in metabolic diseases. <i>Endocrine</i> , 2018, 59, 260-274.	1.1	178
14	The Association Between <i>Helicobacter pylori</i> Infection and Insulin Resistance: A Systematic Review. <i>Helicobacter</i> , 2011, 16, 79-88.	1.6	175
15	Leptin in nonalcoholic fatty liver disease: A narrative review. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 60-78.	1.5	170
16	Eradication of <i>Helicobacter pylori</i> may be beneficial in the management of Alzheimer's disease. <i>Journal of Neurology</i> , 2009, 256, 758-767.	1.8	150
17	Extragastric Diseases and <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2015, 20, 40-46.	1.6	150
18	Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. <i>Endocrine</i> , 2020, 67, 1-8.	1.1	150

#	ARTICLE	IF	CITATIONS
19	Clinical complications following thyroid fine-needle biopsy: a systematic review. <i>Clinical Endocrinology</i> , 2009, 71, 157-165.	1.2	149
20	Pharmacotherapy of type 2 diabetes: An update. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 13-42.	1.5	144
21	Adipose tissue, obesity and non-alcoholic fatty liver disease. <i>Minerva Endocrinology</i> , 2017, 42, 92-108.	0.6	135
22	Circulating Irisin in Healthy, Young Individuals: Day-Night Rhythm, Effects of Food Intake and Exercise, and Associations With Gender, Physical Activity, Diet, and Body Composition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3247-3255.	1.8	133
23	Relationship between <i>Helicobacter pylori</i> infection and glaucoma11The authors have no commercial interests in the products or devices mention herein.. <i>Ophthalmology</i> , 2001, 108, 599-604.	2.5	130
24	<i>Helicobacter pylori</i> infection in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 121-126.	1.5	130
25	Sarcopenic obesity. <i>Hormones</i> , 2018, 17, 321-331.	0.9	129
26	Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 272-284.	1.1	124
27	Irisin: A renaissance in metabolism?. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 1037-1044.	1.5	113
28	Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease. <i>Archives of Medical Research</i> , 2021, 52, 25-37.	1.5	112
29	Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women- the six-month effect of risedronate and teriparatide. <i>Osteoporosis International</i> , 2012, 23, 1171-1176.	1.3	111
30	Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months. <i>Osteoporosis International</i> , 2014, 25, 1633-1642.	1.3	111
31	Eradication of <i>Helicobacter pylori</i> May Be Beneficial in the Management of Chronic Open-Angle Glaucoma. <i>Archives of Internal Medicine</i> , 2002, 162, 1237.	4.3	103
32	Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 2220-2228.	3.1	103
33	Increased Cerebrospinal Fluid <i>Helicobacter Pylori</i> Antibody in Alzheimer's Disease. <i>International Journal of Neuroscience</i> , 2009, 119, 765-777.	0.8	96
34	Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. <i>Metabolism: Clinical and Experimental</i> , 2017, 71, 182-197.	1.5	96
35	Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events. <i>International Journal of Obesity</i> , 2015, 39, 156-161.	1.6	95
36	Five-year Survival After <i>Helicobacter pylori</i> Eradication in Alzheimer Disease Patients. <i>Cognitive and Behavioral Neurology</i> , 2010, 23, 199-204.	0.5	94

#	ARTICLE	IF	CITATIONS
37	THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. <i>European Journal of Endocrinology</i> , 2018, 179, R31-R45.	1.9	94
38	Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1297-1306.	1.5	92
39	Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 953-960.	1.2	90
40	Review: Impact of <i>Helicobacter pylori</i> on Alzheimer's disease: What do we know so far?. <i>Helicobacter</i> , 2018, 23, e12454.	1.6	88
41	Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154203.	1.5	88
42	The Emerging Role of Endocrine Disruptors in Pathogenesis of Insulin Resistance: A Concept Implicating Nonalcoholic Fatty Liver Disease. <i>Current Molecular Medicine</i> , 2012, 12, 68-82.	0.6	85
43	A potential impact of chronic <i>Helicobacter pylori</i> infection on Alzheimer's disease pathobiology and course. <i>Neurobiology of Aging</i> , 2012, 33, e3-e4.	1.5	83
44	Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. <i>Metabolism: Clinical and Experimental</i> , 2019, 101, 154005.	1.5	83
45	<i>H. pylori</i> and Parkinson's disease: Meta-analyses including clinical severity. <i>Clinical Neurology and Neurosurgery</i> , 2018, 175, 16-24.	0.6	78
46	Increased levels of <i>Helicobacter pylori</i> IgG antibodies in aqueous humor of patients with primary open-angle and exfoliation glaucoma. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2003, 241, 884-890.	1.0	77
47	Thyroid nodules - Stepwise diagnosis and management. <i>Hormones</i> , 2007, 6, 101-119.	0.9	74
48	Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 66-82.	1.5	72
49	Alzheimer's disease and <i>Helicobacter pylori</i> infection: Defective immune regulation and apoptosis as proposed common links. <i>Medical Hypotheses</i> , 2007, 68, 378-388.	0.8	71
50	The Potential Adverse Role of Leptin Resistance in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 50-54.	1.1	69
51	Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 295.	0.9	69
52	Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 161-167.	1.5	69
53	New Aspects of <i>Helicobacter pylori</i> Infection Involvement in Gastric Oncogenesis. <i>Journal of Surgical Research</i> , 2008, 146, 149-158.	0.8	62
54	Nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1007-1016.	1.5	62

#	ARTICLE	IF	CITATIONS
55	Obesity and thyroid cancer: epidemiologic associations and underlying mechanisms. <i>Obesity Reviews</i> , 2013, 14, 1006-1022.	3.1	61
56	Predictors of long-term remission in patients with Gravesâ€™ disease: a single center experience. <i>Endocrine</i> , 2013, 44, 448-453.	1.1	60
57	Challenge in the Pathogenesis of Autoimmune Pancreatitis: Potential Role of Helicobacter pylori Infection via Molecular Mimicry. <i>Gastroenterology</i> , 2007, 133, 368-369.	0.6	54
58	Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. <i>Current Vascular Pharmacology</i> , 2020, 18, 172-181.	0.8	54
59	Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy. <i>Metabolism: Clinical and Experimental</i> , 2017, 73, 1-8.	1.5	53
60	Potential impact of Helicobacter pylori-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis. <i>Metabolism: Clinical and Experimental</i> , 2018, 87, 18-24.	1.5	53
61	The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. <i>Clinical Endocrinology</i> , 2010, 72, 752-757.	1.2	52
62	Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. <i>Clinical Endocrinology</i> , 2013, 79, 499-503.	1.2	52
63	Micro-Ultrasoundâ€“Guided vs Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2021, 205, 1254-1262.	0.2	52
64	Induction of apoptosis as a proposed pathophysiological link between glaucoma and Helicobacter pylori infection. <i>Medical Hypotheses</i> , 2004, 62, 378-381.	0.8	51
65	Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives. <i>Current Vascular Pharmacology</i> , 2019, 17, 546-555.	0.8	51
66	Primary open-angle glaucoma: pathophysiology and treatment. <i>Lancet</i> , The, 2004, 364, 1311-1312.	6.3	50
67	Helicobacter pylori and multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2007, 188, 187-189.	1.1	50
68	An update on the validity of irisin assays and the link between irisin and hepatic metabolism. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 937-942.	1.5	50
69	Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease. <i>Hormones</i> , 2013, 12, 405-416.	0.9	49
70	Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. <i>Osteoporosis International</i> , 2015, 26, 2521-2527.	1.3	49
71	Leptin in Health and Disease: Facts and Expectations at its Twentieth Anniversary. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 5-12.	1.5	49
72	Irisin: A true, circulating hormone. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1611-1618.	1.5	48

#	ARTICLE	IF	CITATIONS
73	Active <i>Helicobacter pylori</i> Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 933.	1.0	48
74	Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. <i>Pituitary</i> , 2012, 15, 25-29.	1.6	47
75	Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1013-1025.	1.9	47
76	A Systematic Review of Cases Reporting Needle Tract Seeding Following Thyroid Fine Needle Biopsy. <i>World Journal of Surgery</i> , 2010, 34, 844-851.	0.8	46
77	Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naïve Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3206-3212.	1.8	46
78	Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases. <i>Current Molecular Medicine</i> , 2011, 11, 696-707.	0.6	45
79	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. <i>Metabolism: Clinical and Experimental</i> , 2020, 113, 154413.	1.5	45
80	New Molecular Concepts of Barrett's Esophagus: Clinical Implications and Biomarkers. <i>Journal of Surgical Research</i> , 2005, 125, 189-212.	0.8	44
81	Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2011, 12, 498-503.	1.0	44
82	Histological Presence of <i>Helicobacter pylori</i> ; Bacteria in the Trabeculum and Iris of Patients with Primary Open-Angle Glaucoma. <i>Ophthalmic Research</i> , 2012, 47, 150-156.	1.0	44
83	Emerging and future therapies for nonalcoholic steatohepatitis in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1937-1946.	0.9	42
84	Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in nonalcoholic fatty liver disease: a randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1805-1809.	2.2	41
85	<i>Helicobacter pylori</i> : an intruder involved in conspiring glaucomatous neuropathy. <i>British Journal of Ophthalmology</i> , 2009, 93, 1413-1415.	2.1	40
86	Denosumab Treatment for Juvenile Paget's Disease: Results From Two Adult Patients With Osteoprotegerin Deficiency (a Balkan Mutation in the <i>TNFRSF11B</i> Gene). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 703-707.	1.8	38
87	Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. <i>European Journal of Pharmacology</i> , 2019, 863, 172661.	1.7	38
88	Alzheimer's disease and gastrointestinal microbiota; impact of <i>Helicobacter pylori</i> infection involvement. <i>International Journal of Neuroscience</i> , 2021, 131, 289-301.	0.8	38
89	Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. <i>International Journal of Clinical Practice</i> , 2011, 65, 679-683.	0.8	37
90	Off-label uses of denosumab in metabolic bone diseases. <i>Bone</i> , 2019, 129, 115048.	1.4	37

#	ARTICLE	IF	CITATIONS
91	A proposed role of human defensins in <i>Helicobacter pylori</i> -related neurodegenerative disorders. <i>Medical Hypotheses</i> , 2014, 82, 368-373.	0.8	36
92	Cardio-cerebrovascular disease and <i>Helicobacter pylori</i> -related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. <i>International Journal of Cardiology</i> , 2017, 229, 17-18.	0.8	36
93	Acromegaly: presentation, morbidity and treatment outcomes at a single centre. <i>International Journal of Clinical Practice</i> , 2011, 65, 896-902.	0.8	35
94	Clinical vertebral fractures following denosumab discontinuation. <i>Endocrine</i> , 2016, 54, 271-272.	1.1	35
95	<i>Helicobacter pylori</i> infection and esophageal adenocarcinoma: a review and a personal view. <i>Annals of Gastroenterology</i> , 2017, 31, 8-13.	0.4	33
96	Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society. <i>Bone</i> , 2019, 127, 401-418.	1.4	33
97	Combination and sequential treatment in women with postmenopausal osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 477-490.	0.9	33
98	Normal-tension glaucoma and Alzheimer's disease: <i>Helicobacter pylori</i> as a possible common underlying risk factor. <i>Medical Hypotheses</i> , 2007, 68, 228-229.	0.8	32
99	Pituitary incidentalomas: a single-centre experience. <i>International Journal of Clinical Practice</i> , 2011, 65, 172-177.	0.8	32
100	<i>Helicobacter pylori</i> infection and Parkinson's disease: apoptosis as an underlying common contributor. <i>European Journal of Neurology</i> , 2012, 19, e56.	1.7	32
101	Juvenile Paget disease. <i>Metabolism: Clinical and Experimental</i> , 2018, 80, 15-26.	1.5	32
102	Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort. <i>Hormone and Metabolic Research</i> , 2019, 51, 134-140.	0.7	32
103	From the "little brain" gastrointestinal infection to the "big brain" neuroinflammation: A proposed fast axonal transport pathway involved in multiple sclerosis. <i>Medical Hypotheses</i> , 2009, 73, 781-787.	0.8	31
104	Upper Gastrointestinal Carcinogenesis: <i>H. pylori</i> and Stem Cell Cross-Talk. <i>Journal of Surgical Research</i> , 2011, 166, 255-264.	0.8	31
105	The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4155-e4162.	1.8	31
106	Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone. <i>Journal of Bone and Mineral Metabolism</i> , 2008, 26, 635-641.	1.3	30
107	Guillain-Barré syndrome. <i>Lancet Neurology</i> , The, 2008, 7, 1080-1081.	4.9	30
108	RANKL inhibition for the management of patients with benign metabolic bone disorders. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1085-1102.	1.9	30

#	ARTICLE	IF	CITATIONS
109	Effects of mastic gum <i>Pistacia lentiscus</i> var. <i>Chia</i> on innate cellular immune effectors. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 143-149.	0.8	30
110	Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. <i>Bone</i> , 2012, 50, 1130-1134.	1.4	30
111	EFFECT OF <i>HELICOBACTER PYLORI</i> ERADICATION ON HEPATIC STEATOSIS, NAFLD FIBROSIS SCORE AND HSENSI IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: a MR imaging-based pilot open-label study. <i>Arquivos De Gastroenterologia</i> , 2014, 51, 261-268.	0.3	30
112	Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation. <i>Rheumatology</i> , 2015, 54, 908-914.	0.9	30
113	Selenium and selenoprotein P in nonalcoholic fatty liver disease. <i>Hormones</i> , 2020, 19, 61-72.	0.9	30
114	Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. <i>Metabolism: Clinical and Experimental</i> , 2020, 104, 154144.	1.5	30
115	Circulating tumor necrosis factor- α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3002-3014.	1.4	30
116	Acute changes in serum osteoprotegerin and receptor activator for nuclear factor- κ B ligand levels in women with established osteoporosis treated with teriparatide. <i>European Journal of Endocrinology</i> , 2008, 158, 411-415.	1.9	29
117	Familial prevalence of autoimmune disorders in multiple sclerosis in Northern Greece. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1091-1101.	1.4	29
118	Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. <i>Annals of Hepatology</i> , 2013, 12, 749-757.	0.6	29
119	<i>Helicobacter pylori</i> infection, dementia and primary open-angle glaucoma: are they connected?. <i>BMC Ophthalmology</i> , 2015, 15, 24.	0.6	29
120	Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e390-e400.	1.8	29
121	Histological alterations following thyroid fine needle biopsy: A systematic review. <i>Diagnostic Cytopathology</i> , 2009, 37, 455-465.	0.5	28
122	Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 183-189.	0.8	28
123	Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154318.	1.5	28
124	<i>Helicobacter pylori</i> may be involved in cognitive impairment and dementia development through induction of atrophic gastritis, vitamin B-12-folate deficiency, and hyperhomocysteinemia sequence. <i>American Journal of Clinical Nutrition</i> , 2007, 86, 805-806.	2.2	27
125	Serum vitamin B12 and folate levels in patients with non-alcoholic fatty liver disease. <i>International Journal of Food Sciences and Nutrition</i> , 2012, 63, 659-666.	1.3	27
126	Activin A and follistatin in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1550-1558.	1.5	27

#	ARTICLE	IF	CITATIONS
127	Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 706-712.	1.3	26
128	Impact of reactive oxygen species generation on <i>Helicobacter pylori</i> -related extragastric diseases: a hypothesis. <i>Free Radical Research</i> , 2017, 51, 73-79.	1.5	26
129	Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach?. <i>Hepatology</i> , 2018, 68, 389-389.	3.6	26
130	A perspective on risk factors for esophageal adenocarcinoma: emphasis on <i>Helicobacter pylori</i> infection. <i>Annals of the New York Academy of Sciences</i> , 2019, 1452, 12-17.	1.8	26
131	The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. <i>Bone</i> , 2020, 138, 115478.	1.4	26
132	<i>Helicobacter pylori</i> and gastro-oesophageal reflux disease. <i>Lancet</i> , The, 2006, 368, 986.	6.3	25
133	Re: <i>Helicobacter Pylori</i> Infection and Colorectal Cancer Risk: Evidence From a Large Population-Based Case-Control Study in Germany. <i>American Journal of Epidemiology</i> , 2012, 176, 566-567.	1.6	25
134	The Effect of Leptin Replacement on Parathyroid Hormone, RANKL-Osteoprotegerin Axis, and Wnt Inhibitors in Young Women With Hypothalamic Amenorrhea. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2252-E2258.	1.8	25
135	New Aspects of Regulatory Signaling Pathways and Novel Therapies in Pancreatic Cancer. <i>Current Molecular Medicine</i> , 2008, 8, 12-37.	0.6	24
136	The Effect of Zoledronic Acid on Serum Dickkopf-1, Osteoprotegerin, and RANKL in Patients with Paget's Disease of Bone. <i>Hormone and Metabolic Research</i> , 2009, 41, 846-850.	0.7	24
137	Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1291-1297.	1.5	24
138	Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. <i>Journal of Bone and Mineral Metabolism</i> , 2016, 34, 447-456.	1.3	24
139	Obesity: seize the day, fight the fat. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 1-5.	1.5	24
140	ÂVaspin, resistin, retinol-binding protein-4, interleukin-1Î± and interleukin-6 in patients with nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2016, 15, 705-14.	0.6	24
141	Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies. <i>Journal of Surgical Oncology</i> , 2005, 90, 249-259.	0.8	23
142	Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. <i>International Journal of Clinical Practice</i> , 2008, 62, 919-924.	0.8	23
143	Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. <i>Hormones</i> , 2011, 10, 174-195.	0.9	23
144	The Emerging Role of <i>Helicobacter Pylori</i> -Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration. <i>Current Molecular Medicine</i> , 2018, 17, 389-404.	0.6	23

#	ARTICLE	IF	CITATIONS
145	Helicobacter pylori infection and colorectal carcinoma: pathologic aspects. Journal of Gastrointestinal Oncology, 2012, 3, 377-9.	0.6	23
146	Nonalcoholic fatty liver disease: lifestyle and quality of life. Hormones, 2022, 21, 41-49.	0.9	23
147	Novel Advances in the Association Between <i>Helicobacter pylori</i> Infection, Metabolic Syndrome, and Related Morbidity. Helicobacter, 2015, 20, 405-409.	1.6	22
148	Similar late effects of a 7-week orthodox religious fasting and a time restricted eating pattern on anthropometric and metabolic profiles of overweight adults. International Journal of Food Sciences and Nutrition, 2021, 72, 248-258.	1.3	22
149	Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis. Hormones, 2002, 13, 519-31.	0.9	21
150	Alterations in Serum Thyroid-Related Constituents After Thyroid Fine-Needle Biopsy: A Systematic Review. Thyroid, 2010, 20, 265-271.	2.4	21
151	Impact of <i>Helicobacter pylori</i> on multiple sclerosis-related clinically isolated syndrome. Acta Neurologica Scandinavica, 2016, 133, 268-275.	1.0	21
152	A potential impact of Helicobacter pylori -related galectin-3 in neurodegeneration. Neurochemistry International, 2018, 113, 137-151.	1.9	21
153	Association between Active Helicobacter pylori Infection and Glaucoma: A Systematic Review and Meta-Analysis. Microorganisms, 2020, 8, 894.	1.6	21
154	Association between <i>Helicobacter pylori</i> infection and Guillain-Barré Syndrome: A meta-analysis. European Journal of Clinical Investigation, 2020, 50, e13218.	1.7	21
155	Impact of Helicobacter pylori-Related Metabolic Syndrome Parameters on Arterial Hypertension. Microorganisms, 2021, 9, 2351.	1.6	21
156	Coexistence of Graves' disease, papillary thyroid carcinoma and unilateral benign struma ovarii: Case report and review of the literature. Metabolism: Clinical and Experimental, 2013, 62, 1350-1356.	1.5	20
157	Serum vaspin levels in women with and without gestational diabetes mellitus during pregnancy and postpartum. Cytokine, 2013, 61, 127-132.	1.4	20
158	Rodent models of obesity. Minerva Endocrinologica, 2020, 45, 243-263.	1.7	20
159	Serum homocysteine levels in patients with nonalcoholic fatty liver disease. Annals of Hepatology, 2012, 11, 68-76.	0.6	20
160	Nonlinear Distribution of Adiponectin in Patients With Nonalcoholic Fatty Liver Disease Limits Its Use in Linear Regression Analysis. Journal of Clinical Gastroenterology, 2010, 44, 229-230.	1.1	19
161	Adipocytokines in insulin resistance and non-alcoholic fatty liver disease: The two sides of the same coin. Medical Hypotheses, 2010, 74, 1089-1090.	0.8	19
162	<i>Helicobacter pylori</i> Infection Might Contribute to Esophageal Adenocarcinoma Progress in Subpopulations With Gastroesophageal Reflux Disease and Barrett's Esophagus. Helicobacter, 2012, 17, 402-403.	1.6	19

#	ARTICLE	IF	CITATIONS
163	Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1459-1465.	1.5	19
164	Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. <i>Bone</i> , 2019, 120, 44-49.	1.4	19
165	Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations. <i>Maturitas</i> , 2021, 147, 19-25.	1.0	19
166	A concept of <i>Helicobacter pylori</i> and stress-secreted mast cells' potential involvement in brain metastases. <i>Journal of Neuroimmunology</i> , 2009, 209, 121-122.	1.1	18
167	No Effect of Rosuvastatin in the Zoledronate-Induced Acute-Phase Response. <i>Calcified Tissue International</i> , 2011, 88, 402-408.	1.5	18
168	Role of wingless tail signaling pathway in osteoporosis. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2011, 18, 383-388.	1.2	18
169	Novel aspects of defensins TM involvement in virus-induced autoimmunity in the central nervous system. <i>Medical Hypotheses</i> , 2017, 102, 33-36.	0.8	18
170	Selenoprotein P in Patients with Nonalcoholic Fatty Liver Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 598-602.	0.6	18
171	Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study. <i>Open Cardiovascular Medicine Journal</i> , 2014, 8, 55-60.	0.6	18
172	Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: Data from the ATTICA cohort study. <i>Clinical Nutrition</i> , 2022, 41, 1281-1289.	2.3	18
173	Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. <i>Current Obesity Reports</i> , 2022, 11, 166-179.	3.5	18
174	Combination Therapies for Nonalcoholic Fatty Liver Disease. <i>Journal of Personalized Medicine</i> , 2022, 12, 1166.	1.1	18
175	The Use of Demographic, Ultrasonographic and Scintigraphic Data in the Diagnostic Approach of Thyroid Nodules. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2009, 117, 159-164.	0.6	17
176	<i>Helicobacter pylori</i> with or without its neutrophil-activating protein may be the common denominator associated with multiple sclerosis and neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2010, 16, 376-377.	1.4	17
177	Neuroprotection in glaucoma: Is there a future role of <i>Helicobacter pylori</i> eradication?. <i>Experimental Eye Research</i> , 2011, 92, 436-438.	1.2	17
178	<i>Helicobacter pylori</i> infection and the risk for cardiovascular disease. <i>European Journal of Internal Medicine</i> , 2011, 22, e146-e147.	1.0	17
179	Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone. <i>Osteoporosis International</i> , 2011, 22, 363-367.	1.3	17
180	Associations of Estrogen Receptor Alpha and Beta Gene Polymorphisms with Lipid Levels and Insulin Resistance in Men. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 611-617.	1.5	17

#	ARTICLE	IF	CITATIONS
181	Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Expert Opinion on Investigational Drugs, 2015, 24, 145-157.	1.9	17
182	Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR- β agonists. Metabolism: Clinical and Experimental, 2017, 66, 64-68.	1.5	17
183	<i>Helicobacter pylori</i> , gastric microbiota and gastric cancer relationship: Unrolling the tangle. World Journal of Gastrointestinal Oncology, 2022, 14, 959-972.	0.8	17
184	Subendothelial Carotid Hematoma After Fine-Needle Aspiration Biopsy of a Solitary Thyroid Nodule. Journal of Ultrasound in Medicine, 2008, 27, 1517-1520.	0.8	16
185	A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study. Biomarkers, 2013, 18, 607-613.	0.9	16
186	Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease. Endocrine, 2015, 49, 560-562.	1.1	16
187	Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment. Expert Opinion on Therapeutic Targets, 2015, 19, 299-306.	1.5	16
188	Serum Adiponectin And Insulin-Like Growth Factor 1 In Predominantly Female Patients With Thyroid Cancer: Association With The Histologic Characteristics Of The Tumor. Endocrine Practice, 2016, 22, 68-75.	1.1	16
189	<i>Helicobacter pylori</i> infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?. Metabolism: Clinical and Experimental, 2019, 96, iii-v.	1.5	16
190	Impact of <i>Helicobacter pylori</i> and/or <i>Helicobacter pylori</i> -related metabolic syndrome on incidence of all-cause and Alzheimer's dementia. Alzheimer's and Dementia, 2019, 15, 723-725.	0.4	16
191	<i>Helicobacter pylori</i> infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy. Helicobacter, 2019, 24, e12588.	1.6	16
192	Nonalcoholic fatty liver disease in males with low testosterone concentrations. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1571-1577.	1.8	16
193	Comment on "Effect of biofilm formation by clinical isolates of <i>Helicobacter pylori</i> on the efflux-mediated resistance to commonly used antibiotics". World Journal of Gastroenterology, 2017, 23, 6194-6196.	1.4	16
194	Hypophosphatasia. Journal of Clinical Medicine, 2021, 10, 5676.	1.0	16
195	Endogenous Intact PTH is Suppressed during Teriparatide (rhPTH 1-34) Administration in Postmenopausal Women with Established Osteoporosis. Endocrine Journal, 2008, 55, 613-616.	0.7	15
196	Adiponectin as a potential therapeutic agent for nonalcoholic steatohepatitis. Hepatology Research, 2010, 40, 446-447.	1.8	15
197	Paget's Disease of Bone and Calcium Homeostasis: Focus on Bisphosphonate Treatment. Experimental and Clinical Endocrinology and Diabetes, 2011, 119, 519-524.	0.6	15
198	<i>Helicobacter pylori</i> might contribute to nonalcoholic fatty liver disease-related cardiovascular events by releasing prothrombotic and proinflammatory factors. Hepatology, 2014, 60, 1450-1451.	3.6	15

#	ARTICLE	IF	CITATIONS
199	Serum Levels of Activins, Follistatins, and Growth Factors in Neoplasms of the Breast: A Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 349-358.	1.8	15
200	Eradication of <i>Helicobacter pylori</i> might halt the progress to oesophageal adenocarcinoma in patients with gastro-oesophageal reflux disease and Barrett's oesophagus. <i>Medical Hypotheses</i> , 2007, 68, 1174-1175.	0.8	14
201	<i>Helicobacter pylori</i> may hold a variable role in multiple sclerosis based on ethnicity. <i>Medical Hypotheses</i> , 2008, 71, 614-615.	0.8	14
202	Potential implications of <i>Helicobacter pylori</i> -related neutrophil-activating protein. <i>World Journal of Gastroenterology</i> , 2012, 18, 489.	1.4	14
203	Acute transient thyroid swelling following needle biopsy: An update. <i>Hormones</i> , 2012, 11, 147-150.	0.9	14
204	Lipodystrophy: Time for a global registry and randomized clinical trials to assess efficacy, safety and cost-effectiveness of established and novel medications. <i>Metabolism: Clinical and Experimental</i> , 2017, 72, A4-A10.	1.5	14
205	Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. <i>European Journal of Pharmacology</i> , 2021, 907, 174272.	1.7	14
206	<i>Helicobacter pylori</i> and glaucoma. <i>Ophthalmology</i> , 2003, 110, 2433-2434.	2.5	13
207	Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. <i>Supportive Care in Cancer</i> , 2009, 17, 1329-1330.	1.0	13
208	<i>Helicobacter pylori</i> may be a common denominator associated with systemic and multiple sclerosis. <i>Joint Bone Spine</i> , 2011, 78, 222-223.	0.8	13
209	Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1702-1720.	2.2	13
210	<i>Helicobacter pylori</i> infection as a risk factor for primary open-angle glaucoma. <i>Clinical and Experimental Ophthalmology</i> , 2008, 36, 196-196.	1.3	12
211	<i>Helicobacter pylori</i> Might Contribute to Persistent Cognitive Impairment After Resolution of Overt Hepatic Encephalopathy. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 624.	2.4	12
212	<i>Helicobacter pylori</i> infection may trigger Guillain-Barré syndrome, Fisher syndrome and Bickerstaff brainstem encephalitis. <i>Journal of the Neurological Sciences</i> , 2011, 305, 167-168.	0.3	12
213	Adiponectin in non-alcoholic fatty liver disease treatment: therapeutic perspectives and unresolved dilemmas. <i>International Journal of Clinical Practice</i> , 2011, 65, 373-374.	0.8	12
214	<i>Helicobacter pylori</i> Infection and Insulin Resistance. <i>Helicobacter</i> , 2013, 18, 165-166.	1.6	12
215	Polyautoimmunity in a Greek cohort of multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 225-230.	1.0	12
216	Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview. <i>Hormones</i> , 2019, 18, 65-70.	0.9	12

#	ARTICLE	IF	CITATIONS
217	<i>Helicobacter pylori</i> eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis. <i>Helicobacter</i> , 2020, 25, e12666.	1.6	12
218	Potential impact of <i>Helicobacter pylori</i> -related Galectin-3 on chronic kidney, cardiovascular and brain disorders in decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2020, 52, 121-123.	0.4	12
219	Reconsidering the "protective" hypothesis of <i>Helicobacter pylori</i> infection in eosinophilic esophagitis. <i>Annals of the New York Academy of Sciences</i> , 2020, 1481, 59-71.	1.8	12
220	Thyroid dysfunction and non-alcoholic fatty liver disease. <i>Minerva Endocrinology</i> , 2018, 43, 367-376.	0.6	12
221	Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease. <i>Hormones</i> , 2022, 21, 375-381.	0.9	12
222	Association between <i>Helicobacter pylori</i> infection and Alzheimer's disease in Japan. <i>Journal of Neurology</i> , 2011, 258, 2086-2086.	1.8	11
223	Is Serum IL-17A a Useful Systemic Biomarker in Patients With Langerhans Cell Histiocytosis?. <i>Molecular Therapy</i> , 2012, 20, 6-7.	3.7	11
224	<i>Helicobacter pylori</i> may play a role in both obstructive sleep apnea and metabolic syndrome. <i>Sleep Medicine</i> , 2012, 13, 212-213.	0.8	11
225	Impact of <i>Helicobacter pylori</i> Infection on Colon Oncogenesis. <i>American Journal of Gastroenterology</i> , 2013, 108, 625-626.	0.2	11
226	<i>Helicobacter pylori</i> -related ApoE 4 polymorphism may be associated with dysphagic symptoms in older adults. <i>Ecological Management and Restoration</i> , 2016, 29, 842-842.	0.2	11
227	Active <i>Helicobacter pylori</i> Infection Is a Risk Factor for Colorectal Mucosa: Early and Advanced Colonic Neoplasm Sequence. <i>Gut and Liver</i> , 2017, 11, 733-734.	1.4	11
228	Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?. <i>Metabolism: Clinical and Experimental</i> , 2019, 93, 100-102.	1.5	11
229	Influence of <i>Helicobacter pylori</i> -connected metabolic syndrome on non-alcoholic fatty liver disease and its related colorectal neoplasm high risk. <i>Liver International</i> , 2020, 40, 475-476.	1.9	11
230	<i>Helicobacter pylori</i> infection as a potential risk factor for multiple sclerosis. <i>Medical Hypotheses</i> , 2020, 143, 110135.	0.8	11
231	<i>Helicobacter pylori</i> -Related Metabolic Parameters and Premalignant Gastric Mucosa Histological Lesions in Swiss Bariatric Patients. <i>Microorganisms</i> , 2021, 9, 1361.	1.6	11
232	Systematic review of cases reporting blood extravasation-related complications after thyroid fine-needle biopsy. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2010, 39, 532-41.	0.9	11
233	Pathogenetic links between colorectal neoplasia and Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2006, 64, 298.	0.5	10
234	Effect of Strontium Ranelate on Lumbar Spine Bone Mineral Density in Women with Established Osteoporosis Previously Treated with Teriparatide. <i>Hormone and Metabolic Research</i> , 2009, 41, 559-562.	0.7	10

#	ARTICLE	IF	CITATIONS
235	Paget™s disease of bone: emphasis on treatment with zoledronic acid. <i>Expert Review of Endocrinology and Metabolism</i> , 2009, 4, 423-434.	1.2	10
236	Impact of <i>Helicobacter pylori</i> on chronic hepatitis C-related cognitive dysfunction. <i>Journal of Neuroimmunology</i> , 2011, 233, 254-256.	1.1	10
237	Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell Histiocytosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E618-E621.	1.8	10
238	Circulating fetuin-A in patients with pancreatic cancer: a hospital-based case-control study. <i>Biomarkers</i> , 2014, 19, 660-666.	0.9	10
239	Prevalence and determinants of type 2 diabetes mellitus in a Greek adult population. <i>Hormones</i> , 2016, 15, 88-98.	0.9	10
240	Adiponectin and vitamin D-binding protein are independently associated at birth in both mothers and neonates. <i>Endocrine</i> , 2018, 59, 164-174.	1.1	10
241	Impact of <i>Helicobacter pylori</i> and/or <i>Helicobacter pylori</i> -related metabolic syndrome on gastroesophageal reflux disease- <i>Barrett's esophagus</i> -esophageal adenocarcinoma sequence. <i>Helicobacter</i> , 2018, 23, e12534.	1.6	10
242	Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154781.	1.5	10
243	Molecular Links Between Alzheimer's Disease and Gastrointestinal Microbiota: Emphasis on <i>Helicobacter pylori</i> Infection Involvement. <i>Current Molecular Medicine</i> , 2019, 20, 3-12.	0.6	10
244	Induction of Interleukin-8 Expression by <i>Helicobacter Pylori</i> Infection in Patients with Endoscopy-Negative Gastroesophageal Reflux Disease. <i>American Journal of Gastroenterology</i> , 2004, 99, 2500-2501.	0.2	9
245	Multiple sclerosis and seizures: possible role of <i>Helicobacter pylori</i> . <i>European Journal of Neurology</i> , 2011, 18, e116-e116.	1.7	9
246	<i>Helicobacter pylori</i> induced cognitive dysfunction might be associated with falls and fractures in cirrhosis. <i>Hepatology</i> , 2013, 57, 1284-1284.	3.6	9
247	Association between <i>Helicobacter pylori</i> burden and Alzheimer's disease. <i>European Journal of Neurology</i> , 2014, 21, e100-e100.	1.7	9
248	The intriguing connections of leptin to hyperparathyroidism. <i>Endocrine</i> , 2017, 57, 376-387.	1.1	9
249	Acute Liver Failure. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 89-101.	1.1	9
250	Trimebutine Maleate Monotherapy for Functional Dyspepsia: A Multicenter, Randomized, Double-Blind Placebo Controlled Prospective Trial. <i>Medicina (Lithuania)</i> , 2020, 56, 339.	0.8	9
251	Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1913-1919.	1.8	9
252	Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough. <i>Journal of Clinical Densitometry</i> , 2021, 24, 338-340.	0.5	9

#	ARTICLE	IF	CITATIONS
253	The trimebutine effect on <i>Helicobacter pylori</i> -related gastrointestinal tract and brain disorders: A hypothesis. <i>Neurochemistry International</i> , 2021, 144, 104938.	1.9	9
254	Diabetes mellitus: 100 years since the discovery of insulin. <i>Metabolism: Clinical and Experimental</i> , 2021, 118, 154737.	1.5	9
255	Microbes and Alzheimer' disease: lessons from <i>H. pylori</i> and GUT microbiota. <i>European Review for Medical and Pharmacological Sciences</i> , 2019, 23, 1845-1846.	0.5	9
256	Epidemiologic Analysis of Thyroid Fine Needle Aspiration Biopsies over a Period of 18 Years (1987-2004). <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2008, 116, 496-500.	0.6	8
257	Greek and Israeli Patterns of <i>Helicobacter pylori</i> Infection and Their Association With Glaucoma: Similarities or Diversities?. <i>Journal of Glaucoma</i> , 2008, 17, 503-504.	0.8	8
258	No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial. <i>Clinical Endocrinology</i> , 2009, 70, 522-526.	1.2	8
259	Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 314-319.	1.3	8
260	<i>Helicobacter pylori</i> may play an important role in both axonal type Guillain-Barré syndrome and acute inflammatory demyelinating polyradiculoneuropathy. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 520.	0.6	8
261	<i>Helicobacter pylori</i> -Related Impact on Glaucoma Pathophysiology. , 2015, 56, 8029.		8
262	Intracellular leptin signaling following effective weight loss. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 888-895.	1.5	8
263	Asporin levels are low in patients with nonalcoholic fatty liver disease and increase after vitamin E treatment. <i>Hormones</i> , 2019, 18, 519-521.	0.9	8
264	Impact of nitric oxide's bidirectional role on glaucoma: focus on <i>Helicobacter pylori</i> -related nitrosative stress. <i>Annals of the New York Academy of Sciences</i> , 2020, 1465, 10-28.	1.8	8
265	Impact of <i>Helicobacter pylori</i> -linked metabolic syndrome on non-alcoholic fatty liver disease and its connected atrial fibrillation risk. <i>Liver International</i> , 2020, 40, 2036-2037.	1.9	8
266	Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing. <i>Medical Hypotheses</i> , 2021, 146, 110379.	0.8	8
267	Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation. <i>Calcified Tissue International</i> , 2021, 108, 587-594.	1.5	8
268	<i>Helicobacter pylori</i> Infection as a Risk Factor for Both Primary Open-Angle Glaucoma and Pseudoexfoliative Glaucoma in Thessaloniki Eye Study. <i>American Journal of Ophthalmology</i> , 2011, 152, 1079-1080.	1.7	7
269	<i>Helicobacter pylori</i> might be a potential therapeutic target in epilepsy. <i>Medical Hypotheses</i> , 2011, 76, 763.	0.8	7
270	Papillary thyroid microcarcinoma presenting as lymph node metastasis - a diagnostic challenge: case report and systematic review of literature. <i>Hormones</i> , 2012, 11, 419-427.	0.9	7

#	ARTICLE	IF	CITATIONS
271	Potential Oncogenic Properties of Mobilized Stem Cells in a Subpopulation of Inflammatory Bowel Disease Patients Infected with <i>Helicobacter pylori</i> . <i>Inflammatory Bowel Diseases</i> , 2013, 19, E27-E29.	0.9	7
272	Aquaporin 4, <i>Helicobacter pylori</i> and potential implications for neuromyelitis optica. <i>Journal of Neuroimmunology</i> , 2013, 263, 162-163.	1.1	7
273	<i>Helicobacter pylori</i> infection, insulin resistance and nonalcoholic fatty liver disease. <i>Medical Hypotheses</i> , 2014, 82, 795.	0.8	7
274	Fetuin-A levels and free leptin index are reduced in patients with chronic lymphocytic leukemia: a hospital-based case-control study. <i>Leukemia and Lymphoma</i> , 2016, 57, 577-584.	0.6	7
275	<i>Helicobacter pylori</i> -related metabolic syndrome as predictor of progression to esophageal carcinoma in a subpopulation-based Barrett's esophagus cohort. <i>Gastrointestinal Endoscopy</i> , 2017, 85, 462-463.	0.5	7
276	Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?. <i>Calcified Tissue International</i> , 2018, 103, 107-108.	1.5	7
277	Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls. <i>Hormone and Metabolic Research</i> , 2019, 51, 112-119.	0.7	7
278	Treatment of nonalcoholic fatty liver disease: from adult trials to perspectives in the management of children and adolescents. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 247-251.	0.9	7
279	Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation. <i>Journal of Clinical Densitometry</i> , 2021, 24, 591-596.	0.5	7
280	The potentially dual-faceted nature of fetuin-A in <i>Helicobacter pylori</i> infection and insulin resistance. <i>Clinics</i> , 2011, 66, 911-912.	0.6	7
281	Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 852-862.	0.6	7
282	The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass. <i>Clinical Endocrinology</i> , 2012, 77, 816-822.	1.2	6
283	Glaucoma and <i>Helicobacter pylori</i> : Eyes "wide open". <i>Digestive and Liver Disease</i> , 2012, 44, 962-963.	0.4	6
284	<i>Helicobacter pylori</i> Infection and Serum Adiponectin. <i>Helicobacter</i> , 2013, 18, 321-322.	1.6	6
285	<i>Helicobacter pylori</i> -related metabolic syndrome might justify earlier colorectal cancer screening. <i>Gastrointestinal Endoscopy</i> , 2014, 80, 188-189.	0.5	6
286	<i>Helicobacter pylori</i> Associated With Obstructive Sleep Apnea Might Contribute to Sleep, Cognition, and Driving Performance Disturbances in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1547.	2.4	6
287	A potential impact of <i>Helicobacter pylori</i> infection on both obstructive sleep apnea and atrial fibrillation-related stroke. <i>Sleep Medicine</i> , 2017, 34, 256.	0.8	6
288	Circulating periostin in patients with nonalcoholic fatty liver disease. <i>Endocrine</i> , 2017, 56, 438-441.	1.1	6

#	ARTICLE	IF	CITATIONS
289	Endocrine and metabolic disorders interplaying with non-alcoholic fatty liver disease. <i>Minerva Endocrinology</i> , 2017, 42, 89-91.	0.6	6
290	Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. <i>Hormones</i> , 2018, 17, 573-579.	0.9	6
291	Helicobacter pylori Infection and Gastroesophageal Reflux Disease-Barrett's Esophagus-Esophageal Adenocarcinoma Sequence. <i>American Journal of Gastroenterology</i> , 2018, 113, 1723-1724.	0.2	6
292	Multiple Bidirectionality Brain-Gut Interactions in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018, 155, 1651-1652.	0.6	6
293	Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, vi-xi.	1.5	6
294	Update on the association between non-alcoholic fatty liver disease and Helicobacter pylori infection. <i>International Journal of Clinical Practice</i> , 2021, 75, e13737.	0.8	6
295	Denosumab for the treatment of primary pediatric osteoporosis. <i>Osteoporosis International</i> , 2021, 32, 2377-2381.	1.3	6
296	Potential impact of Helicobacter pylori-related metabolic syndrome and Galectin-3 on liver, chronic kidney and brain disorders. <i>Metabolism: Clinical and Experimental</i> , 2021, 118, 154736.	1.5	6
297	Prevalence and determinants of type 2 diabetes mellitus in a Greek adult population. <i>Hormones</i> , 2016, , .	0.9	6
298	Multiple Sclerosis, Idiopathic Dilated Cardiomyopathy, and Insulin-dependent Diabetes Mellitus. <i>Neurologist</i> , 2011, 17, 172-175.	0.4	5
299	Active Helicobacter pylori infection on colorectal mucosa adenomatous polyp adenocarcinoma sequence. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 243-244.	0.8	5
300	Circulating homocysteine in nonalcoholic fatty liver disease. <i>European Journal of Internal Medicine</i> , 2015, 26, 152-153.	1.0	5
301	Comments to the Editor concerning the paper entitled "The microbiome and ophthalmic disease" by Baim et al.. <i>Experimental Biology and Medicine</i> , 2019, 244, 430-432.	1.1	5
302	Role of autophagy in gastric carcinogenesis. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1244-1262.	0.8	5
303	Patients with established gastro-esophageal reflux disease might benefit from eradication. <i>Annals of Gastroenterology</i> , 2014, 27, 352-356.	0.4	5
304	Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need. <i>Current Medical Research and Opinion</i> , 2022, 38, 885-888.	0.9	5
305	Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: A systematic review and a meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1853-1864.	1.4	5
306	Sustained Clinical Inactivity and Stabilization of GH/IGF-1 Levels in an Acromegalic Patient after Discontinuation of Somatostatin Analogue Treatment. <i>Endocrine Journal</i> , 2008, 55, 351-357.	0.7	4

#	ARTICLE	IF	CITATIONS
307	Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 108-110.	1.3	4
308	Primary hyperparathyroidism and incidental multifocal metastatic papillary thyroid carcinoma in a man. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2010, 54, 578-582.	1.3	4
309	Denosumab and bisphosphonates: Rivals or potential "partners"? A "hybrid" molecule hypothesis. <i>Medical Hypotheses</i> , 2011, 77, 109-111.	0.8	4
310	<i>Helicobacter pylori</i> and insulin resistance association: Not just a myth, not yet a fact. <i>Saudi Journal of Gastroenterology</i> , 2011, 17, 425.	0.5	4
311	Hpn protein as a mediator between <i>Helicobacter pylori</i> infection and Alzheimer's disease in sub-populations worldwide. <i>Medical Hypotheses</i> , 2012, 78, 349-350.	0.8	4
312	Further data on the association between <i>Helicobacter pylori</i> infection and primary open-angle glaucoma. <i>Clinical Ophthalmology</i> , 2012, 6, 243.	0.9	4
313	Sulfated oxysterols as candidates for the treatment of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 755-758.	1.5	4
314	Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy. <i>Advances in Medical Sciences</i> , 2013, 58, 38-43.	0.9	4
315	<i>Helicobacter pylori</i> and Colorectal Cancer Risk"Letter. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 365-365.	1.1	4
316	Obstructive Sleep Apnea and Environmental Contributors for Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1055-1056.	2.4	4
317	<i>Helicobacter pylori</i> might contribute to cancer and/or bone marrow-derived stem cell-related gastrointestinal oncogenesis. <i>Oncogene</i> , 2015, 34, 670-670.	2.6	4
318	Association between cirrhosis and <i>Helicobacter pylori</i> -related brain pathologies. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 183.	0.8	4
319	Periostin on the road to nonalcoholic fatty liver disease. <i>Endocrine</i> , 2016, 51, 4-6.	1.1	4
320	<i>Helicobacter pylori</i> eradication to prevent cardio-cerebrovascular disease: Are current data useful for clinical practice?. <i>International Journal of Cardiology</i> , 2017, 233, 92.	0.8	4
321	Outliers of bone metabolic diseases. <i>Metabolism: Clinical and Experimental</i> , 2018, 80, 1-4.	1.5	4
322	The Effect of Trimebutine and/or <i>Helicobacter pylori</i> Eradication on the Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, and Functional Dyspepsia Overlapping Disorders. <i>Journal of Neurogastroenterology and Motility</i> , 2019, 25, 473-474.	0.8	4
323	<i>Helicobacter pylori</i> infection and diabetes mellitus. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 845-846.	1.8	4
324	Gastroesophageal reflux disease, irritable bowel syndrome and functional dyspepsia as overlapping conditions: focus on effect of trimebutine. <i>Annals of Gastroenterology</i> , 2019, 32, 318.	0.4	4

#	ARTICLE	IF	CITATIONS
325	Homocysteine in nonalcoholic steatohepatitis: seemingly a paradox revisited. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 270-271.	0.5	4
326	The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis. <i>Exploration of Medicine</i> , 2020, 1, 170-183.	1.5	4
327	infection and liver cirrhosis: possible association with hepatic encephalopathy and/or post-hepatic encephalopathy cognitive impairment in patients with portal hypertension. <i>Annals of Gastroenterology</i> , 2014, 27, 285.	0.4	4
328	Infectious thyroiditis as a complication of fine-needle biopsy: a systematic review. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 673-679.	1.2	3
329	Dual-Energy X-Ray Absorptiometry and Quantitative Ultrasound in Patients With Paget's Disease of Bone Before and After Treatment With Zoledronic Acid: Association With Serum Bone Markers and Dickkopf-1. <i>Journal of Clinical Densitometry</i> , 2010, 13, 190-196.	0.5	3
330	Modern industrialisation may increase primary open-angle glaucoma prevalence through easier transmission of <i>Helicobacter pylori</i> infection. <i>Medical Hypotheses</i> , 2011, 76, 766-767.	0.8	3
331	Editorial [Hot Topic Adiponectin in Health and Disease: Current Evidence and Therapeutic Perspectives (Guest Editor: Stergios A. Polyzos)]. <i>Current Medicinal Chemistry</i> , 2012, 19, 5425-5426.	1.2	3
332	Trying to treat diabetes in Greek crisis. <i>International Journal of Clinical Practice</i> , 2012, 66, 515-515.	0.8	3
333	Is <i>Helicobacter pylori</i> the usual suspect behind gastroesophageal reflux disease and dacryostenosis?. <i>Medical Hypotheses</i> , 2013, 81, 147.	0.8	3
334	Relationship between <i>Helicobacter pylori</i> infection and autoimmune disorders. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, e73-4.	1.4	3
335	Serum visfatin in nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2014, 13, 150-151.	0.6	3
336	Nonalcoholic fatty liver disease and polycystic ovary syndrome. <i>Annals of Hepatology</i> , 2015, 14, 941-943.	0.6	3
337	Colchicine to decrease inflammation and fibrosis in patients with metabolic dysregulation. <i>Medical Hypotheses</i> , 2016, 95, 34.	0.8	3
338	Letter: <i>Helicobacter pylori</i> -related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 576-577.	1.9	3
339	Letter: <i>Helicobacter pylori</i> in lean and obese patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 637-638.	1.9	3
340	Potential Impact of <i>Helicobacter Pylori</i> on Hepatic Encephalopathy Pathophysiology. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1087-1088.	1.1	3
341	<i>Helicobacter pylori</i> infection and gastrointestinal tract cancer biology: considering a double-edged sword reflection. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 2487-2488.	2.4	3
342	<i>Helicobacter pylori</i> Infection: One More Contributor to Nonalcoholic Fatty Liver Disease Pathophysiology. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 624-626.	1.1	3

#	ARTICLE	IF	CITATIONS
343	Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care?. <i>Medicina (Lithuania)</i> , 2020, 56, 133.	0.8	3
344	A mutation in NOTCH2 gene first associated with Hajduâ€“Cheney syndrome in a Greek family: diversity in phenotype and response to treatment. <i>Endocrine</i> , 2021, 71, 208-215.	1.1	3
345	Helicobacter pylori, Sleeve Gastrectomy, and Gastroesophageal Reflux Disease: Is There a Relation?. <i>Obesity Surgery</i> , 2021, 31, 1839-1840.	1.1	3
346	Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?. <i>Metabolism: Clinical and Experimental</i> , 2021, 121, 154796.	1.5	3
347	Impact of Helicobacter pylori-related Metabolic Syndrome and Gastroesophageal Reflux Disease on the Risk of Acute Myocardial Infarction. <i>Journal of Neurogastroenterology and Motility</i> , 2021, 27, 147-148.	0.8	3
348	A potential impact of Helicobacter pylori infection on minimal hepatic encephalopathy pathobiology. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 405-412.	0.5	3
349	Helicobacter Pylori-Related Vitamin B12 Deficiency: A Potential Contributor in Neuropsychiatric Disorders. <i>Indian Journal of Psychological Medicine</i> , 2015, 37, 475-476.	0.6	3
350	Impact of Body Mass Index on the Age of Relapsing-Remitting Multiple Sclerosis Onset: A Retrospective Study. <i>Neurology International</i> , 2021, 13, 517-526.	1.3	3
351	Correspondence on 'Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis' by Rizos et al. <i>Heart</i> , 2022, 108, 657.1-657.	1.2	3
352	Cilofexor for the Treatment of Nonalcoholic Steatohepatitis. <i>Current Vascular Pharmacology</i> , 2022, 20, 111-113.	0.8	3
353	Coincidental thyroid papillary microcarcinoma in a patient treated for a toxic adenoma of the thyroid. <i>Archives of Iranian Medicine</i> , 2011, 14, 149-51.	0.2	3
354	Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer. <i>Hormones</i> , 2022, 21, 513-514.	0.9	3
355	Irritable bowel syndrome associated with mitral valve prolapse and autonomic and haemostatic abnormalities in children, adolescents and adults with migraine. <i>Acta Neurologica Scandinavica</i> , 2011, 123, 366-367.	1.0	2
356	Helicobacter pylori's potential association with epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2012, 21, 151.	0.9	2
357	Long-term effects of thyroid fine-needle biopsy on the thyroid-related biochemical parameters. <i>International Journal of Clinical Practice</i> , 2012, 66, 602-609.	0.8	2
358	Thyrotropin receptor autoantibodies and early miscarriages in patients with Hashimoto thyroiditis: a caseâ€“control study. <i>Gynecological Endocrinology</i> , 2013, 29, 793-796.	0.7	2
359	Body mass index and socioeconomic status measured in adolescence, country of origin, and the incidence of gastroesophageal adenocarcinoma in a cohort of 1 million men. <i>Cancer</i> , 2014, 120, 768-768.	2.0	2
360	Active Helicobacter pylori infection is associated with colorectal mucosa â€“ adenomatous polyp â€“ early and advanced adenocarcinoma sequence. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 381-382.	0.6	2

#	ARTICLE	IF	CITATIONS
361	Additional data on <i>Helicobacter pylori</i> and hepatitis C virus infections and lymphoma association. <i>European Journal of Internal Medicine</i> , 2014, 25, e7-e8.	1.0	2
362	Bone Marrow-Derived Stem Cells in Pathogenesis of <i>Helicobacter pylori</i> -Associated Gastrointestinal Cancer. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e129.	1.3	2
363	CD44 and <i>Helicobacter pylori</i> -related colon oncogenesis. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2015, 36, 1249-1249.	0.5	2
364	<i>Helicobacter pylori</i> -related chronic hepatitis C infection and the risk for cardiovascular disease. <i>Liver International</i> , 2017, 37, 1082-1082.	1.9	2
365	Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity. <i>Metabolism: Clinical and Experimental</i> , 2017, 71, 198-201.	1.5	2
366	Sixty-six years of <i>Metabolism, Clinical and Experimental</i> : The journey of a journal and opportunities and challenges looking ahead. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, A4-A9.	1.5	2
367	CHA1 and MACK as noninvasive indices for nonalcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 1587-1587.	1.9	2
368	Metabolic syndrome components including high abdominal obesity and sarcopenia in patients with inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2019, 32, 214.	0.4	2
369	Vitamin D Deficiency and Unclear Abdominal Pain in Patients from Low- and Middle-Income Countries. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4607.	1.2	2
370	Impact of occupational stress on irritable bowel syndrome pathophysiology and potential management in active duty noncombat Greek military personnel: a multicenter prospective survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 954-963.	0.8	2
371	Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 73-76.	0.7	2
372	A potential impact of <i>Helicobacter pylori</i> -related sarcopenia on severity of portal hypertension. <i>Liver International</i> , 2021, 41, 1168-1169.	1.9	2
373	Îrisin levels in postmenopausal women with an incident hip fracture. <i>Endocrine</i> , 2021, 73, 719-722.	1.1	2
374	Irisin in nonalcoholic fatty liver disease: need for an updated meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2021, 121, 154818.	1.5	2
375	Periostin and sclerostin levels in juvenile Paget's disease. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2017, 14, 269.	1.0	2
376	Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease. <i>Minerva Endocrinology</i> , 2023, 48, .	0.6	2
377	The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis. <i>Bone</i> , 2022, 158, 116354.	1.4	2
378	Primary open-angle glaucoma. <i>New England Journal of Medicine</i> , 2009, 360, 2679; author reply 2679-80.	13.9	2

#	ARTICLE	IF	CITATIONS
379	Impact of <i>Helicobacter pylori</i> -related metabolic syndrome with hyperhomocysteinemia on extragastric pathologies. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 407-408.	1.4	2
380	Letter to the Editor Regarding "The Association of <i>Helicobacter pylori</i> , Eradication, and Early Complications of Laparoscopic Sleeve Gastrectomy" by Abeid et al.. <i>Obesity Surgery</i> , 2022, 32, 2079.	1.1	2
381	The effect of zoledronic acid on serum Dickkopf-1, osteoprotegerin and rankl in patients with paget's disease of bone. <i>Bone</i> , 2009, 44, S289.	1.4	1
382	Insulin resistance and therapy: Cross-talk between phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways. <i>Medical Hypotheses</i> , 2009, 72, 610.	0.8	1
383	<i>Helicobacter pylori</i> may be involved in stroke pathophysiology by altering tumor necrosis factor- α and matrix metalloproteinases. <i>European Journal of Neurology</i> , 2011, 18, e76-e76.	1.7	1
384	Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone. <i>Clinical Rheumatology</i> , 2011, 30, 149-150.	1.0	1
385	Association between <i>Helicobacter pylori</i> infection and fibromyalgia syndrome. <i>Clinical Rheumatology</i> , 2011, 30, 301-302.	1.0	1
386	Comment on: Jeon et al. <i>Helicobacter pylori</i> Infection Is Associated With an Increased Rate of Diabetes. <i>Diabetes Care</i> 2012;35:520-525. <i>Diabetes Care</i> , 2012, 35, e53-e53.	4.3	1
387	A rebuttal to the potential anti-tumour benefit of <i>Helicobacter pylori</i> -induced neutrophil-activating protein. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 445-446.	2.0	1
388	Ki-67 and Bax expression in esophageal mucosa might have implications in ablative therapies for Barrett's esophagus, dysplasia, and adenocarcinoma. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 283-284.	1.3	1
389	A possible impact of common worldwide environmental agents on the prognosis of critically ill cirrhotic patients. <i>Liver International</i> , 2014, 34, 1127-1128.	1.9	1
390	Letter: apoptosis and hepatic fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 996-996.	1.9	1
391	Eradication of <i>Helicobacter pylori</i> infection might have a positive impact on subpopulations with endoscopic gastro-oesophageal reflux disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 123.	0.8	1
392	Bone and Fat Interplay in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, E22.	0.9	1
393	Prediction of atheromatic plaque evolution in carotids using features extracted from the arterial geometry. , 2015, 2015, 6556-9.		1
394	<i>Helicobacter pylori</i> infection and oesophageal adenocarcinoma. <i>Cancer Epidemiology</i> , 2016, 42, 206-207.	0.8	1
395	<i>Helicobacter pylori</i> on portal hypertension-related hepatic encephalopathy. <i>Immunopharmacology and Immunotoxicology</i> , 2017, 39, 105-106.	1.1	1
396	Obesity and the nervous system: more questions. <i>Lancet Neurology</i> , The, 2017, 16, 772-773.	4.9	1

#	ARTICLE	IF	CITATIONS
397	Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis. <i>Endocrine</i> , 2018, 62, 487-489.	1.1	1
398	Adiponectin and vitamin D-binding protein concentrations are independently associated in apparently healthy women but not men: a validation cohort. <i>Hormones</i> , 2019, 18, 99-102.	0.9	1
399	Potential Impact of <i>Helicobacter pylori</i> Infection on Reflux Disease Sequence. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 200-201.	1.1	1
400	Adult hypophosphatasia treated with reduced frequency of teriparatide dosing. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2021, 21, 584-589.	0.1	1
401	Comments on "Dose-related meta-analysis for omega-3 fatty acids supplementation on major adverse cardiovascular events". <i>Clinical Nutrition</i> , 2022, , .	2.3	1
402	Spirolactone Revisited. <i>Journal of Clinical Hypertension</i> , 2011, 13, 783-784.	1.0	0
403	Letter: low risk of colorectal cancer in a Greek cohort of inflammatory bowel disease patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1001-1002.	1.9	0
404	P1017 : Circulating sclerostin and DICKKOPF-1 in patients with Nonalcoholic Fatty Liver Disease. <i>Journal of Hepatology</i> , 2015, 62, S729.	1.8	0
405	Homocysteine in nonalcoholic steatohepatitis: A reply. <i>European Journal of Internal Medicine</i> , 2016, 35, e40-e41.	1.0	0
406	Potential molecular aspects of <i>Helicobacter pylori</i> -related hyperplastic polyp development and progression. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 851-852.	0.8	0
407	Comment on "Therapeutic Application of an Extract of <i>Helicobacter pylori</i> Ameliorates the Development of Allergic Airway Disease". <i>Journal of Immunology</i> , 2018, 200, 3027.1-3027.	0.4	0
408	The relationship between <i>Helicobacter pylori</i> -related microbiota dysbiosis and gastrointestinal tract pathologies. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 806-807.	0.6	0
409	Letter: <i>Helicobacter pylori</i> in proton pump inhibitor-associated biliary disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 313-314.	1.9	0
410	Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis. <i>Annals of Hepatology</i> , 2020, 19, 579-580.	0.6	0
411	Letter to the editor re: Li et al. (2020), "The potential role of bacteria in pancreatic cancer: A systematic review". <i>Carcinogenesis</i> , 2020, 41, 539-540.	1.3	0
412	Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion. <i>Endocrine</i> , 2021, 73, 223-225.	1.1	0
413	Impact of <i>Helicobacter pylori</i> -related Microbial Dysbiosis in the Pathogenesis of Metabolic Syndrome and Gastrointestinal Dysmotility Disorders. <i>Journal of Neurogastroenterology and Motility</i> , 2021, 27, 653-654.	0.8	0
414	Visual Vignette. <i>Endocrine Practice</i> , 2012, 18, 108.	1.1	0

#	ARTICLE	IF	CITATIONS
415	Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, L89-L90.	1.8	0
416	National consensus on <i>Helicobacter pylori</i> infection: the next-day challenge. <i>Annals of Gastroenterology</i> , 2020, 33, 324-325.	0.4	0
417	Letter: <i>Helicobacter pylori</i> infection and its role in oesophageal adenocarcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1215-1216.	1.9	0
418	Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2019, 19, 253-257.	0.1	0
419	Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid. <i>Endokrynologia Polska</i> , 2012, 63, 312-5.	0.3	0
420	Potential Impact of Active <i>Helicobacter pylori</i> Infection with or without Concomitant Metabolic Syndrome on Colorectal Cancer Invasion and Mortality. <i>Israel Medical Association Journal</i> , 2018, 20, 725-726.	0.1	0
421	GM-CSF as a potential candidate of a vaccine-induced reduction of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2022, 27, e12884.	1.6	0
422	Potential Impact of Active <i>H. pylori</i> Infection-Related Metabolic Syndrome on Preeclampsia Among Pregnant Women [Letter]. <i>International Journal of Women's Health</i> , 0, Volume 14, 845-846.	1.1	0